Breaking News
No way! The best 4K TV streaming stick is somehow just $17 for Prime Day ‘The decision is sickening’: MAHA leaders feel betrayed by Supreme Court ruling on Roundup weed killer Why Jamie Foxx And Robert Downey Jr.'s Movie All-Star Weekend Still Hasn't Come Out Sacramento ‘builds bridges, not walls’ as it officially partners with Mexican city South Korea's LS Cable starts key work at U.S. subsea plant Laura Ingraham: The Supreme Court played clean-up Apple (AAPL) Stock Trades Down, Here Is Why How GM is building a more sustainable energy ecosystem
Signalz Online
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
Biotech Clinical Trials

Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board

Source: news.google.com

Published: Jun 23, 2026 19:40

Read Original Source
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board  BioSpace
Detailed source content is still being fetched from the original article. Use the source link above for the live story.

Courtesy Link

https://news.google.com/rss/articles/CBMixgJBVV95cUxPVWFUeDk3akhOWnNZUU9pbW1aaGdXQ2NLZklOaHRwMkJZLWJ4UHIzMlF3ZGdZeDJiVFhJVmJjVnlBejVIc2RHcW1fcXh5SkhQd3E2OWlfZmFjaFRIcXg5TzVVRG9tNXBuZFAwbC01RjNEODJWbVVLQWVCdDE4bVY1QkpqWFVCSGZvUW1YY3oyMHhYbXJKQlFmUlh1a2pNSW1oRjJSOThIWXRZTkJVaVVtcFd5dV9RdlViZTd3cVRKRW16dDc1MTJkRkhub2lxaHlRSVZkZmpGUDk2Yl9sWlZrdGF1TmJWSDlrSGMzaVVONjViLWJwaFNMZFU4ckhZQVE1ZVBUTF9fdF9uOXlPdlpIQlJjbXFHZFZEZWlHWGJZM1BkNWpFQ192NTN4NkljaDR1VFdaTjZaQjRrOUpLNEx6YWFnb3NWZw?oc=5

Related Stories

More from this topic and section

Add Shortcut

Add Newsfeed to your home screen

Open this site faster like an app from your phone home screen.

X in 3s